A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066

Summary

This is a study to compare the efficacy of IPX066 and CLE in subjects with advanced Parkinson's disease.

Timeline

Start

2010-05

Primary completion

2012-01

Completion

2012-01

Outcome

Met primary endpoint

release “IPX066 demonstrated statistically significant improvement over carbidopa-levodopa plus entacapone in reducing the percentage of "off time" during waking hours” amneal.com ↗

Publications

• Morgan JC, Dhall R, Rubens R, Khanna S, Gupta S. Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations. Parkinsons Dis. 2018 Oct 22;2018:9763057. doi: 10.1155/2018/9763057. eCollection 2018.

Drugs

Indications